Sipp Industries, Inc. announce a Research and Development agreement with Calypso Pharmaceuticals. The aim is to create a nano-emulsified topical formulation in collaboration with AVEINA, SIPP's wellness-focused brand specializing in nanotechnology formulations, to target melanoma using Peptide P16. Peptide P16, a synthetic, cell-penetrating peptide derived from the melanoma suppressor P16, has demonstrated promising results in selectively killing melanoma cells while sparing normal cells.

Utilizing Peptide P16 in nano emulsions for melanoma treatment offers a promising strategy to enhance apoptosis and effectively target cancer cells. Calypso Pharmaceuticals' nanotechnology produces particle sizes ranging from 1 nm to 600 nm and can deliver therapeutic agents like P16 peptides more efficiently to tumor sites. This targeted delivery system improves drug solubility and stability, achieving over 95% bioavailability while minimizing systemic toxicity.

By utilizing P16 in nano emulsions, the peptide can penetrate cancer cells more effectively, inducing apoptosis specifically in melanoma cells without harming normal tissues. This approach not only enhances the therapeutic index but also reduces side effects, making it a valuable method for treating melanoma and potentially other diseases. The research initiative will focus on formulating and optimizing the nano-emulsified topical to ensure maximum penetration and efficacy of Peptide P16 in treating melanoma.

Both companies are dedicated to rigorous testing and clinical trials to validate the safety and effectiveness of the product.